Clinical Trial Data Sharing: IOM Envisions Open And Closed Doors
This article was originally published in The Pink Sheet Daily
Institute of Medicine report calls for greater, faster availability of full clinical trial data sets, but with no authority and many loopholes, impact on status quo may be minimal.
You may also be interested in...
GlaxoSmithKline, Pfizer, and Biogen are among those participating in new data-sharing and analytics platform; 2,500 trials currently available to researchers.
Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.